Background/Aims: To analyze the long-term changes in retinal perfusion and functional improvement induced by radial optic neurotomy (RON) in central retinal vein occlusion (CRVO). Methods: Sixty-three eyes of 63 consecutive patients with CRVO were included. Twenty-eight (44.5%) patients underwent RON and 35 (55.5%) were followed as a control group. Time of arteriovenous transit and visual acuity were determined at baseline and after 1-year follow-up. Results: After 1 year, retinal perfusion status improved in 63.1% of operated eyes and 14.3% of controls (p = 0.048). The improvement in arteriovenous retinal transit was statistically significant (p = 0.023) only in the RON group. The visual improvement in the RON group was significantly better (p = 0.043) than in the control group. Moreover, the development of chorioretinal anastomosis was significantly higher (p = 0.036) after RON than in controls and correlated with better functional results. In operated eyes there was a lower incidence of CRVO-related complications. Conclusion: RON improved retinal perfusion and achieved a better functional outcome. The measurement of perfusion changes as presented here may be useful for monitoring CRVO and assessing other treatment modalities.

The Eye Disease Case-Control Study Group: Risk factors for central retinal vein occlusion. Arch Ophthalmol 1996;114:545–554.
Liebreich R: Apoplexia retinae. Albrecht von Graefes Arch Ophthalmol 1855;1:346–351.
Green WR, Chan CC, Hutchins GM, Terry JM: Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc 1981;79:371–422.
Williamson TH: A ‘throttle’ mechanism in the central retinal vein in the region of the lamina cribrosa. Br J Ophthalmol 2007;91:1190–1193.
The Central Vein Occlusion Study Group: Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 1997;115:486–491.
Opremcak EM, Bruce RA, Lomeo MD, Ridenour CD, Letson AD, Rehmar AJ: Radial optic neurotomy for central retinal vein occlusion: a retrospective pilot study of 11 consecutive cases. Retina 2001;21:408–415.
García-Arumí J, Boixadera A, Martinez-Castillo V, Castilo R, Dou A, Corcóstegui B: Chorioretinal anastomosis after radial optic neurotomy for central retinal vein occlusion. Arch Ophthalmol 2003;121:1385–1391.
The Central Vein Occlusion Study Group: Baseline and early natural history report: the Central Vein Occlusion Study. Arch Ophthalmol 1993;111:1087–1095.
Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E: Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol 2002;86:247–248.
Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W, Schmidt-Erfurth U: Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 2008;92:518–522.
Ferrara DC, Koizumi H, Spaide RF: Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol 2007;144:864–871.
Priglinger SG, Wolf AH, Kreutzer TC, Kook D, Hofer A, Strauss RW, Alge CS, Kunze C, Haritoglou C, Kampik A: Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-months results of a prospective trial. Retina 2007;27:1004–1012.
Vasco-Posada J: Modification of the circulation in the posterior pole of the eye. Ann Ophthalmol 1972;4:48–59.
Quiroz-Mercado H, Sanchez Buenfil E, Guerrero-Naranjo JL, Ochoa-Contreras D, Ruiz-Cruz M, Marcellino G, Damico DJ: Successful erbium:YAG laser-induced chorioretinal venous anastomosis for the management of ischemic central retinal vein occlusion: a report of two cases. Graefes Arch Clin Exp Ophthalmol 2001;239:872–875.
Mirshahi A, Roohipoor R, Lashay A, Mohammadi SF, Mansouri MR: Surgical induction of chorioretinal venous anastomosis in ischaemic central retinal vein occlusion: a non-randomised controlled clinical trial. Br J Ophthalmol 2005;89:64–69.
Stefansson E, Novack RL, Hatchell DL: Vitrectomy prevents retinal hypoxia in branch retinal occlusion. Invest Ophthalmol Vis Sci 1990;31:284–289.
Hikichi T, Konno S, Trempe CL: Role of the vitreous in central retinal vein occlusion. Retina 1995;15:29–33.
Weizer JS, Stinnett SS, Fekrat S: Radial optic neurotomy as treatment for central retinal vein occlusion. Am J Ophthalmol 2003;136:814–819.
Weinberg DV, Seddon JM: Venous occlusive diseases of the retina; in Albert DM, Jakobiec FA (eds): Principles and Practice of Ophthalmology. Philadelphia, Saunders, 1994, p 735.
Fuller JJ, Mason JO III, White MF Jr, McGwin G Jr, Emond TL, Feist RM: Retinochoroidal collateral veins protect against anterior segment neovascularization. Arch Ophthalmol 2003;121:332–336.
Nomoto H, Shiraga F, Yamaji H, Kageyama M, Takenaka H, Baba T, Tsuchida Y: Evaluation of radial optic neurotomy for central retinal vein occlusion by indocianine green videoangiography and image analysis. Am J Ophthalmol 2004;138:612–619.
Zambarakji HJ, Ghazi-Nouri S, Schadt M, Bunce C, Hykin PG, Charteris DG: Vitrectomy and radial optic neurotomy for central retinal vein occlusion: effects on visual acuity and macular anatomy. Graefes Arch Clin Exp Ophthalmol 2005;243:397–405.
Spaide RF, Klacnik JM, Gross NE: Retinal choroidal collateral circulation after radial optic neurotomy correlated with the lessening of macular edema. Retina 2004;24:356–359.
Horio N, Horiguchi M: Retinal blood flow and macular edema after radial optic neurotomy for central retinal vein occlusion. Am J Ophthalmol 2006;141:31–34.
Shuler RK, Fekrat S: Does radial optic neurotomy alter retinal blood flow in eyes with a central retinal vein occlusion? Am J Ophthalmol 2006;141:145–146.
Opremcak EM, Rehmar AJ, Ridenour CD, Kurz DE: Radial optic neurotomy for central retinal vein occlusion: 117 consecutive cases. Retina 2006;26:297–305.
Hasselbach HC, Ruefer F, Feltgen N, Schneider U, Bopp S, Hansen LL, Hoerauf H, Bartz-Schmidt U, Roider J: Treatment of central retinal vein occlusion by radial optic neurotomy in 107 cases. Graefes Arch Clin Exp Ophthalmol 2007;245:1145–1156.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.